Tradestie Institutional Equity Comparison Engine

DARE vs MBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MBIO Overall Edge

MBIO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mustang Bio, Inc. (MBIO) driven by superior Growth & Margin, Momentum & Technical while DARE counters with relative strength in Valuation. Fundamentally, DARE trades at 1.3x Forward P/E with -813.4% operating margin (+499.6% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DARE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner DARE
DARE 1.3x vs MBIO N/M Fwd P/E
Growth & Margin Winner MBIO
Op Margin -813.4% vs 0.0% ยท YoY +499.6% vs +0.0%
Momentum & Technical Winner MBIO
1Y -69.1% vs -68.4% ยท 52W Pos 0% vs 3%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
DARE NASDAQ
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-11.13% 1D
Market Cap $12.9M
1M Return -19.38%
1Y Return -69.09%
Forward P/E 1.3x
Unified AI Score
45.7 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 64.0
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap $3.2M
1M Return +3.22%
1Y Return -68.44%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DARE -69.09% MBIO -68.44% Spread: +0.94 pp (MBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DARE TTM Op. Margin: -813.4% MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DARE vs MBIO. Trailing 12-month operating profitability (DARE -813.4% vs MBIO 0.0%) and valuation multiples (DARE 1.3x vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DARE (5) vs MBIO (3)
Institutional Metric DARE MBIO Criterion Row Winner
Market Capitalization Scale $12.9M $3.2M Larger Scale Tie
Trailing P/E Ratio Valuation 1.3x N/M Lower Multiple DARE
Forward P/E Ratio Valuation 1.3x N/M Lower Multiple DARE
Revenue Growth (YoY) Growth +499.6% +0.0% Higher Growth DARE
Operating Margin (TTM) Profitability -813.4% 0.0% Higher Margin MBIO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2543.1% -43.1% Higher ROE MBIO
52-Week Range Position Momentum 0% ($1โ€“$4) 3% ($0โ€“$1) Stronger Trend MBIO
Beta / 30D Volatility Risk Regime 1.40ฮฒ ยท 62% Vol 0.68ฮฒ ยท 87% Vol Lower Realized Risk DARE
Unified Institutional Score Composite Signal 45.7 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite DARE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DARE vs MBIO Buy Guide
DARE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DARE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DARE nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.